MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584798 | Name: Deprenyl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deprenyl is a selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease.

Chemical Structure

Deprenyl
Deprenyl
CAS#2323-36-6

Theoretical Analysis

MedKoo Cat#: 584798

Name: Deprenyl

CAS#: 2323-36-6

Chemical Formula: C13H17N

Exact Mass: 187.1361

Molecular Weight: 187.29

Elemental Analysis: C, 83.37; H, 9.15; N, 7.48

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Deprenyl; Deprenil; (+-)-Deprenyl
IUPAC/Chemical Name
Phenethylamine, N,alpha-dimethyl-N-2-propynyl-
InChi Key
MEZLKOACVSPNER-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3
SMILES Code
C#CCN(C)C(C)CC1=CC=CC=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 187.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Knoll J, Miklya I. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP). Life Sci. 2016 Dec 15;167:32-38. doi: 10.1016/j.lfs.2016.10.023. Epub 2016 Oct 22. PubMed PMID: 27777099. 2: Miklya I. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). Mol Psychiatry. 2016 Nov;21(11):1499-1503. doi: 10.1038/mp.2016.127. Epub 2016 Aug 2. Review. PubMed PMID: 27480491. 3: Horváthová F, Danielisová V, Domoráková I, Solár P, Rybárová S, Hodorová I, Mihalik J. The effect of R-(-)-deprenyl administration on antioxidant enzymes in rat testis. Eur J Pharmacol. 2016 Oct 5;788:21-28. doi: 10.1016/j.ejphar.2016.06.015. Epub 2016 Jun 9. PubMed PMID: 27292162. 4: Buccino P, Kreimerman I, Zirbesegger K, Porcal W, Savio E, Engler H. Automated radiosynthesis of [(11)C]L-deprenyl-D2 and [(11)C]D-deprenyl using a commercial platform. Appl Radiat Isot. 2016 Apr;110:47-52. doi: 10.1016/j.apradiso.2015.12.051. Epub 2015 Dec 24. PubMed PMID: 26760951. 5: Kalász H, Magyar K, Szőke É, Adeghate E, Adem A, Hasan MY, Nurulain SM, Tekes K. Metabolism of selegiline [(-)-deprenyl)]. Curr Med Chem. 2014;21(13):1522-30. Review. PubMed PMID: 24350849. 6: Lesniak A, Aarnio M, Jonsson A, Norberg T, Nyberg F, Gordh T. High-throughput screening and radioligand binding studies reveal monoamine oxidase-B as the primary binding target for d-deprenyl. Life Sci. 2016 May 1;152:231-7. doi: 10.1016/j.lfs.2016.03.058. Epub 2016 Apr 5. PubMed PMID: 27058977. 7: Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993 Jan 21;328(3):176-83. PubMed PMID: 8417384. 8: Mihalik J, Mašlanková J, Solár P, Horváthová F, Hubková B, Almášiová V, Šoltés J, Švaňa M, Rybárová S, Hodorová I. The effect of R-(-)-deprenyl administration on reproductive parameters of rat males. Eur J Pharmacol. 2015 May 5;754:148-52. doi: 10.1016/j.ejphar.2015.02.030. Epub 2015 Feb 26. PubMed PMID: 25725114. 9: Ryu I, Ryu MJ, Han J, Kim SJ, Lee MJ, Ju X, Yoo BH, Lee YL, Jang Y, Song IC, Chung W, Oh E, Heo JY, Kweon GR. L Deprenyl exerts cytotoxicity towards acute myeloid leukemia through inhibition of mitochondrial respiration. Oncol Rep. 2018 Dec;40(6):3869-3878. doi: 10.3892/or.2018.6753. Epub 2018 Oct 1. PubMed PMID: 30272370. 10: Miklya I. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline. Pharmacol Rep. 2014 Jun;66(3):453-8. doi: 10.1016/j.pharep.2013.11.003. Epub 2014 Apr 3. PubMed PMID: 24905523. 11: Yohn SE, Reynolds S, Tripodi G, Correa M, Salamone JD. The monoamine-oxidase B inhibitor deprenyl increases selection of high-effort activity in rats tested on a progressive ratio/chow feeding choice procedure: Implications for treating motivational dysfunctions. Behav Brain Res. 2018 Apr 16;342:27-34. doi: 10.1016/j.bbr.2017.12.039. Epub 2017 Dec 29. PubMed PMID: 29292157. 12: Knoll J, Baghy K, Eckhardt S, Ferdinandy P, Garami M, Harsing LG Jr, Hauser P, Mervai Z, Pocza T, Schaff Z, Schuler D, Miklya I. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain. Life Sci. 2017 Aug 1;182:57-64. doi: 10.1016/j.lfs.2017.06.010. Epub 2017 Jun 13. PubMed PMID: 28623006. 13: Magyar K, Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology. 2004 Jan;25(1-2):233-42. Review. PubMed PMID: 14697898. 14: Knoll J. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes. Biomed Pharmacother. 1995;49(4):187-95. Review. PubMed PMID: 7669938. 15: Szende B, Barna G, Magyar K. Cytoprotective effect of (-)-deprenyl, (-)desmethyl-deprenyl and (-)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells. J Neural Transm (Vienna). 2010 Jun;117(6):695-8. doi: 10.1007/s00702-010-0413-8. Epub 2010 May 9. PubMed PMID: 20454984. 16: Lange KW, Riederer P, Youdim MB. Biochemical actions of l-deprenyl (selegiline). Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):734-41. Review. PubMed PMID: 7995015. 17: Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc. 1993 Nov;41(11):1219-25. Review. PubMed PMID: 8227897. 18: Löscher W, Lehmann H. L-deprenyl (selegiline) exerts anticonvulsant effects against different seizure types in mice. J Pharmacol Exp Ther. 1996 Jun;277(3):1410-7. PubMed PMID: 8667204. 19: Schneider LS, Tariot PN, Goldstein B. Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):750-6. Review. PubMed PMID: 7995017. 20: Magyar K, Pálfi M, Tábi T, Kalász H, Szende B, Szöko E. Pharmacological aspects of (-)-deprenyl. Curr Med Chem. 2004 Aug;11(15):2017-31. Review. PubMed PMID: 15279565.